Tiny nanodevice monitors cancer treatment

A tiny nanoscale device can accurately measure a patient’s blood for methotrexate – a commonly used but potentially toxic cancer drug – in under 60 seconds, according to biomedical instrument designer Jean-François Masson, and Joelle Pelletier, a DHFR enzyme specialist, both at the Chemistry Department, University of Montreal.

Source: University of Montreal
Source: University of Montreal

Crucially, the device’s optical system can rapidly gauge the optimal dose of methotrexate a patient needs, while minimising the drug’s adverse effects.
Methotrexate can block the enzyme dihydrofolate reductase (DHFR), which is active in the synthesis of DNA precursors and thus promotes cancer cell proliferation – but it is highly toxic, so closely monitoring the drug’s concentration in a patient’s serum is vital.
Currently, a device using fluorescent bioassays to measure light polarisation produced by a drug sample is used – but this is a cumbersome, expensive platform that only experienced personnel can manipulate.

Six years ago, Pelletier and Masson investigated how to simplify the procedure. In the course of their research they developed and manufactured the miniaturised device that works by surface plasmon resonance. Put simply, it measures serum methotrexate concentration through gold nanoparticles on the surface of a receptacle. In ‘competing’ with methotrexate to block the enzyme, the gold nanoparticles change the colour of light detected by the instrument and that colour reflects the exact concentration of the drug in the blood sample.

In tests, measurements from nanoparticles device proved as accurate, Masson pointed out, yet took under 60 seconds to produce, compared to 30 minutes for current devices used, and they were obtained easily by lab technicians inexperienced in surface plasmon resonance.

The new device is small and needs little manipulation of samples, so could soon be used at the bedside and/or in a GP surgery.

10.11.2014

More on the subject:
Read all latest stories

Related articles

Photo

Article • Diversity, transparency, flexibility

Building trustworthy AI systems for cancer imaging

Building artificial intelligence (AI) tools that clinicians and patients can trust, and easily use and understand, are core to the technology being successfully deployed in healthcare settings.

Photo

News • Prevention improvement

Bowel cancer: most cases diagnosed outside of screening programmes

More than 70% of patients with bowel cancer are not diagnosed using screening programmes meaning diagnoses are often made late, when the cancer is at an advanced stage, according to new research.

Photo

Article • Ovarian cancer and endometriosis detection

Women’s health imaging: PET/CT and T2*w MR show promise

Diagnostic imaging in women’s health advances: PET/CT might provide a more accurate imaging alternative to CT in ovarian cancer. T2*-weighted MR imaging in deep endometriosis detection also shows…

Related products

Image Information Systems – iQ-View

Reading

Image Information Systems – iQ-View

IMAGE Information Systems Europe GmbH
Nova Biomedical – StatStrip Glucose/Ketone*

Blood Glucose

Nova Biomedical – StatStrip Glucose/Ketone*

Nova Biomedical Corporation
Sarstedt - COVID-19 virus diagnostics products

Saliva Collection

Sarstedt - COVID-19 virus diagnostics products

SARSTEDT AG & CO. KG
Sarstedt – CSF false-bottom tube

CSF and Alzheimer’s Disease Diagnostics

Sarstedt – CSF false-bottom tube

SARSTEDT AG & CO. KG
Sarstedt – Tempus600 Vita

Sample Logistics

Sarstedt – Tempus600 Vita

SARSTEDT AG & CO. KG
Subscribe to Newsletter